LIANBIO-ADR (LIAN)
US53000N1081 - ADR
Why Is LianBio (LIAN) Stock Moving Today?
LianBio stock is incredibly volatile on Friday as heavy trading rocks LIAN amid plans for a voluntary delisting of the shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!
LianBio to voluntarily delist from Nasdaq (NASDAQ:LIAN)
LianBio plans to voluntarily delist its ADSs from Nasdaq and expects to be quoted on the OTC Markets Group Inc., ensuring continued trading.
LianBio Announces Voluntarily Delisting from Nasdaq
LianBio declares $4.80 special dividend (NASDAQ:LIAN)
LianBio (LIAN) declares $4.80/share special dividend. Payable March 11; for shareholders of record Feb. 27; ex-div Feb. 26. See LIAN Dividend Scorecard, Yield C
LianBio to wind down its operations, delist its ADS; shares up (NASDAQ:LIAN)
LianBio (LIAN) said it has decided to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American D
LianBio Announces Completion of Strategic Review
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend
LianBio Announces Completion of Strategic Review
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of...
BofA downgrades LianBio to underperform, cites pipeline optionality (NASDAQ:LIAN)
BofA downgraded LianBio (LIAN) to underperform, citing the company’s lower pipeline optionality since its deal to sell the Asian rights for mavacamten to Bristo
Johnson & Johnson inks licensing deal with LianBio (NASDAQ:LIAN)
LianBio (LIAN) inks a deal with Janssen unit of Johnson & Johnson (JNJ) to assign rights for its radioenhancer NBTXR3 in certain Asian markets. Read more here.
LianBio assigns rights for NBTXR3 in China and more Asian markets (NASDAQ:LIAN)
LianBio enters agreement with Janssen to assign rights for NBTXR3 in China, South Korea, Singapore, and Thailand, receiving $25M one-time payment and...
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative...
联拓生物签署协议转让其在中国及其他亚洲市场对NBTXR3的权利
上海和新泽西州普林斯顿, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
LianBio Announces Departure of Chief Financial Officer
LianBio Announces Departure of Chief Financial Officer
SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative...
联拓生物宣布公司首席财务官离任
上海和新泽西州普林斯顿, Dec. 20, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN），一家致力于为中国和其他主要亚洲市场的患者提供创新药物的生物技术公司，于今日宣布公司首席财务官Yi Larson于2023年12月19日从联拓生物离任，以寻求其他机会。 ...
LianBio announces departure of CEO Yizhe Wang (NASDAQ:LIAN)
LianBio announces the departure of CEO Yizhe Wang and appointment of Adam Stone as Interim CEO.
LianBio Announces Departure of Chief Executive Officer
LianBio Announces Departure of Chief Executive Officer
SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative...
联拓生物宣布公司首席执行官离任
上海和新泽西州普林斯顿, Dec. 20, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN），一家致力于为中国和其他主要亚洲市场的患者提供创新药物的生物技术公司，于今日宣布公司首席执行官王轶喆博士已从联拓生物离任，以寻求其他机会。 ...
联拓生物董事会一致决定不跟进Concentra Biosciences未经邀约的提案
上海和新泽西州普林斯顿, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN），一家致力于为中国和其他主要亚洲市场的患者提供创新药物的生物技术公司，于今日宣布其董事会一致决定不跟进Concentra Biosciences,...
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative...
LianBio confirms buyout offer from Concentra Biosciences (NASDAQ:LIAN)
LianBio (LIAN) confirmed it has received an unsolicited offer from Concentra Biosciences to acquire the company for $4.30 per share in cash, plus a CVR. Read more here.
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
联拓生物确认收到 Concentra Biosciences 未经邀约的提案
上海和新泽西州普林斯顿, Dec. 02, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN）是一家致力于为中国和其他主要亚洲市场的患者提供创新药物的生物技术公司，其董事会于今日确认由 Tang Capital Partners, LP 控股的Concentra...
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology...
LianBio receives buyout offer of $4.30 per share, plus CVR (NASDAQ:LIAN)
Concentra Biosciences offers to acquire LianBio (LIAN) for $4.30 per share in cash, plus a contingency value right. Read more here.
LianBio GAAP EPS of -$0.22 beats by $0.06 (NASDAQ:LIAN)
LianBio, a pharmaceutical company, beats expectations with Q3 GAAP EPS of -$0.22.
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SHANGHAI and PRINCETON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2023.